Novel therapeutic strategies for patients with metastatic triple-negative breast cancer

Triple-negative breast cancer (TNBC) remains the most aggressive subtype of breast cancer. In the presence of distant metastases, the median overall survival does not exceed 14 months. TNBC is an extremely heterogeneous group of tumors, it includes both tumors extremely sensitive to chemotherapy and...

Full description

Bibliographic Details
Main Authors: Inna P. Ganshina, Olga O. Gordeeva, Mariam Sh. Manukian
Format: Article
Language:Russian
Published: IP Habib O.N. 2021-02-01
Series:Современная онкология
Subjects:
Online Access:https://modernonco.orscience.ru/1815-1434/article/viewFile/61149/44238
_version_ 1818843770316128256
author Inna P. Ganshina
Olga O. Gordeeva
Mariam Sh. Manukian
author_facet Inna P. Ganshina
Olga O. Gordeeva
Mariam Sh. Manukian
author_sort Inna P. Ganshina
collection DOAJ
description Triple-negative breast cancer (TNBC) remains the most aggressive subtype of breast cancer. In the presence of distant metastases, the median overall survival does not exceed 14 months. TNBC is an extremely heterogeneous group of tumors, it includes both tumors extremely sensitive to chemotherapy and tumors that require targeted or immunotherapy for the best treatment outcomes. Such subtype features make it difficult to develop a single treatment strategy for all patients. Current perceptions of resistance mechanisms and molecular drivers progression have increased therapeutic opportunities for metastatic TNBC (mTNBC). For example, in the last few years, checkpoint inhibitors and PARP inhibitors have entered into clinical practice in the Russian Federation. This review presents clinical trial data, as well as an algorithm for choosing therapy for patients with TNBC, based on the results of recent clinical studies. The review focuses mainly on drugs registered at the territory of the Russian Federation, that allows to apply these options in everyday clinical practice. Promising directions therapy of mTNBC not registered at the territory of the Russian Federation yet will be showed in a separate review in the next issue in the Journal of Modern Oncology.
first_indexed 2024-12-19T05:03:09Z
format Article
id doaj.art-a99aa8bbbad543218bc93d48c8adcbf6
institution Directory Open Access Journal
issn 1815-1434
1815-1442
language Russian
last_indexed 2024-12-19T05:03:09Z
publishDate 2021-02-01
publisher IP Habib O.N.
record_format Article
series Современная онкология
spelling doaj.art-a99aa8bbbad543218bc93d48c8adcbf62022-12-21T20:35:01ZrusIP Habib O.N.Современная онкология1815-14341815-14422021-02-01224606510.26442/18151434.2020.4.20049555991Novel therapeutic strategies for patients with metastatic triple-negative breast cancerInna P. Ganshina0https://orcid.org/0000-0002-0105-9376Olga O. Gordeeva1https://orcid.org/0000-0002-8266-0218Mariam Sh. Manukian2https://orcid.org/0000-0002-5084-4872Blokhin National Medical Research Center of OncologyBlokhin National Medical Research Center of OncologyBlokhin National Medical Research Center of OncologyTriple-negative breast cancer (TNBC) remains the most aggressive subtype of breast cancer. In the presence of distant metastases, the median overall survival does not exceed 14 months. TNBC is an extremely heterogeneous group of tumors, it includes both tumors extremely sensitive to chemotherapy and tumors that require targeted or immunotherapy for the best treatment outcomes. Such subtype features make it difficult to develop a single treatment strategy for all patients. Current perceptions of resistance mechanisms and molecular drivers progression have increased therapeutic opportunities for metastatic TNBC (mTNBC). For example, in the last few years, checkpoint inhibitors and PARP inhibitors have entered into clinical practice in the Russian Federation. This review presents clinical trial data, as well as an algorithm for choosing therapy for patients with TNBC, based on the results of recent clinical studies. The review focuses mainly on drugs registered at the territory of the Russian Federation, that allows to apply these options in everyday clinical practice. Promising directions therapy of mTNBC not registered at the territory of the Russian Federation yet will be showed in a separate review in the next issue in the Journal of Modern Oncology.https://modernonco.orscience.ru/1815-1434/article/viewFile/61149/44238triple negative breast cancerchemotherapyantiangiogenic therapyimmunotherapyparp inhibitorsdrug therapy
spellingShingle Inna P. Ganshina
Olga O. Gordeeva
Mariam Sh. Manukian
Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
Современная онкология
triple negative breast cancer
chemotherapy
antiangiogenic therapy
immunotherapy
parp inhibitors
drug therapy
title Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
title_full Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
title_fullStr Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
title_full_unstemmed Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
title_short Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
title_sort novel therapeutic strategies for patients with metastatic triple negative breast cancer
topic triple negative breast cancer
chemotherapy
antiangiogenic therapy
immunotherapy
parp inhibitors
drug therapy
url https://modernonco.orscience.ru/1815-1434/article/viewFile/61149/44238
work_keys_str_mv AT innapganshina noveltherapeuticstrategiesforpatientswithmetastatictriplenegativebreastcancer
AT olgaogordeeva noveltherapeuticstrategiesforpatientswithmetastatictriplenegativebreastcancer
AT mariamshmanukian noveltherapeuticstrategiesforpatientswithmetastatictriplenegativebreastcancer